Stock Track | Moderna Plummets 5% as Trump Administration Plans to End Support for Vaccine Aid Organization

Stock Track2025-03-26

Shares of Moderna, Inc. (MRNA) plummeted 5.08% in intraday trading on Wednesday, following reports that the Trump Administration plans to end support for Gavi, a key vaccine aid organization. The news has sent shockwaves through the pharmaceutical industry, particularly affecting companies heavily involved in vaccine production and distribution.

The decision to withdraw support from Gavi could have significant implications for Moderna, a leading COVID-19 vaccine manufacturer. Gavi, the Vaccine Alliance, plays a crucial role in providing vaccines to developing countries and has been instrumental in global vaccination efforts. The potential loss of this support might impact Moderna's vaccine distribution channels and future contracts, leading investors to reassess the company's growth prospects.

This sharp decline in Moderna's stock price outpaces the initial 4.1% drop reported earlier in the day, indicating growing investor concern as the news spreads. The move also affects other vaccine makers, with Novavax reportedly down 2%. As the situation develops, market participants will be closely watching for any official statements from the Trump Administration or Moderna regarding the potential impact of this policy change on the company's operations and financial outlook.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment